Biogen (BIIB) Current Assets (2009 - 2026)
Biogen (BIIB) posted quarterly Current Assets of $7.3 billion for Q2 2026, down 8.31% year-over-year from $8.0 billion in Q2 2025, and down 20.51% quarter-over-quarter from $9.2 billion in Q1 2026.
Biogen (BIIB) Current Assets (2009 - 2026) Analysis & Trends
Biogen's Current Assets history runs 18 years deep, the most recent figure standing at $7.3 billion for Q2 2026.
- In Q2 2026, Current Assets fell 8.31% year-over-year to $7.3 billion; the TTM figure through Jun 2026 stood at $7.3 billion (down 8.31% YoY), while the FY2025 annual figure was $9.0 billion, up 20.35% from the prior year.
- Current Assets for Q2 2026 stood at $7.3 billion, down from $9.2 billion in the prior quarter.
- The five-year high for Current Assets was $10.4 billion in Q2 2023, with the low at $6.8 billion in Q1 2024.
- The 5-year median for Current Assets is $8.2 billion (2023), against an average of $8.4 billion.
- The sharpest annual moves came in 2022 and 2024: Current Assets jumped 36.35% in 2022, then slumped 31.86% in 2024.
- Biogen's Current Assets stood at $9.8 billion in 2022, then decreased by 29.94% to $6.9 billion in 2023, then climbed by 8.71% to $7.5 billion in 2024, then rose by 20.35% to $9.0 billion in 2025, then dropped by 18.59% to $7.3 billion in 2026.
- Business Quant data shows BIIB's Current Assets at $7.3 billion in Q2 2026, $9.2 billion in Q1 2026, and $9.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 7.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.31 Bn |
| Mar 31, 2026 | 9.19 Bn |
| Dec 31, 2025 | 8.97 Bn |
| Sep 30, 2025 | 8.94 Bn |
| Jun 30, 2025 | 7.97 Bn |
| Mar 31, 2025 | 7.63 Bn |
| Dec 31, 2024 | 7.46 Bn |
| Sep 30, 2024 | 6.83 Bn |
| Jun 30, 2024 | 7.11 Bn |
| Mar 31, 2024 | 6.76 Bn |
| Dec 31, 2023 | 6.86 Bn |
| Sep 30, 2023 | 8.45 Bn |
| Jun 30, 2023 | 10.43 Bn |
| Mar 31, 2023 | 9.76 Bn |
| Dec 31, 2022 | 9.79 Bn |
| Sep 30, 2022 | 9.77 Bn |
| Jun 30, 2022 | 9.74 Bn |
| Mar 31, 2022 | 7.92 Bn |
| Dec 31, 2021 | 7.86 Bn |
| Sep 30, 2021 | 7.16 Bn |